Join our daily newsletter At The Bell to receive exclusive market insights
Pro Medicus Ltd (ASX:PME) has signed a $330 million contract with one of the United States’ largest not-for-profit health care systems for delivery of an integrated diagnostic imaging platform built around several of PME’s key products.
The contract – which will stretch over 10 years – was signed between PME subsidiary Visage Imaging and Trinity Health, which is responsible for 93 hospitals, 107 continuing care locations, 142 urgent care locations, and various other services across 26 U.S. states.
It will involve the implementation of the company’s cloud-based Visage 7 Enterprise Imaging Platform, including Visage 7 Open Archive and Visage 7 Workflow modules across Trinity’s health care system, following a transactional licensing model.
As part of this process, Visage will help Trinity migrate from its legacy PACS system (made up of 9 vendors) to Visage Open Archive. Enterprise distribution of images will be provided by Visage 7 to Trinity’s electronic health record (EHR).
PME chief executive Dr Sam Hupert said the contract was an important step in boosting awareness of the company’s products.
“Trinity Health is our largest customer to date and the first with a national footprint,“ he said.
“Our initiative with Trinity Health is noteworthy for its’ scope and scale which will see the Visage 7 platform used by over 650 Radiologists and thousands of clinicians who will benefit from the proven differentiation of Visage 7.”
PME shares have moved upwards following the news, and at 15:08 AEDT, they were trading at $245.35 – a rise of 7.42% since the market opened.
Join the discussion. See what HotCopper users are saying about Pro Medicus and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
